Medical Grand Rounds

*Presented by*

Yale School of Medicine, Department of Internal Medicine

The 2020 & 2021 Recipients of the

Iva Dostanic Physician-Scientist Trainee Award

Rupak Datta, MD

Instructor in Medicine, Section of Infectious Diseases

“Antibiotic Stewardship to Promote Palliative Care in Older Adults Near the End of Life”

Anna Perdigoto, MD, PhD

Clinical Fellow in Medicine (Endocrinology)

“Clinical and Preclinical Insights into the Mechanisms of Checkpoint Inhibitor-induced Diabetes”

**Date: June 24, 2021 Time: 8:30-9:30am**

**Location:** [**https://zoom.us/j/94896766303?pwd=UWFrcG9GNXMvcWZ3YU4ycUc5VEVSdz09**](https://zoom.us/j/94896766303?pwd=UWFrcG9GNXMvcWZ3YU4ycUc5VEVSdz09)

***There is no corporate support for this activity***

This course will fulfill the licensure requirement set forth by the State of Connecticut

**ACCREDITATION:**

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**TARGET AUDIENCE:**

**Attending physicians, house staff, fellows, medical students, PA’s**

**Dr. Datta, NEEDS ASSESSMENT:**

The use of antibiotics during end-of-life care is highly variable. Clinicians need to know about factors associated with antibiotic use during end-of-life care, understand tradeoffs of antibiotic use during end-of-life care, and have knowledge of strategies to promote goal-concordant care of terminal infections.

**LEARNING OBJECTIVES:**

1. To understand the tradeoffs of antibiotic use during end-of-life care

2. To identify factors associated with antibiotic use during end-of-life care

3. To recognize strategies to promote goal-concordant care of terminal infections

**Dr. Perdigoto, NEEDS ASSESSMENT:**

Autoimmune diabetes mellitus is an infrequent but significant side effect of cancer treatment with immune checkpoint inhibitors. Clinicians need to know about the key features of checkpoint inhibitor-induced diabetes and have knowledge of the underlying mechanisms and their therapeutic implications.

**LEARNING OBJECTIVES:**

1. Identify key features of checkpoint inhibitor-induced diabetes, including similarities and differences to spontaneous diabetes

2. Review immunological and islet cell changes that may lead to the development of checkpoint inhibitor-induced diabetes

3. Appreciate potential therapeutic implications of recent insights into the mechanisms of checkpoint inhibitor-induced diabetes

**DESIGNATION STATEMENT**

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

**FACULTY DISCLOSURES:**

Course Director: Vincent Quagliarello, MD - None

Speaker: Rupak Datta, MD- None

Speaker: Anna Perdigoto, MD, PhD- None

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.